These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

97 related items for PubMed ID: 6120678

  • 1. Low CSF GABA in Parkinsonian patients who respond poorly to therapy or suffer from the "on-off" phenomenon.
    Teychenné PF, Ziegler MG, Lake CR, Enna SJ.
    Ann Neurol; 1982 Jan; 11(1):76-9. PubMed ID: 6120678
    [No Abstract] [Full Text] [Related]

  • 2. [Letter: Effect of bromocryptine on the fluctuations following dopa therapy. On-off phenomenon in parkinsonian patients].
    Frattola L, Albizzati MG, Spano PF, Trabucchi M.
    Nouv Presse Med; 1982 Jan; 5(28):1761. PubMed ID: 958891
    [No Abstract] [Full Text] [Related]

  • 3. Dystonia-Parkinson syndrome: differential effects of levodopa and dopamine agonists.
    Klawans HL, Paleologos N.
    Clin Neuropharmacol; 1986 Jan; 9(3):298-302. PubMed ID: 3719575
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Low CSF gamma-aminobutyric acid levels in Parkinson's Disease. Effect of levodopa and carbidopa.
    Manyam BV.
    Arch Neurol; 1982 Jul; 39(7):391-2. PubMed ID: 7103767
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Effect of the putative dopamine D1 agonist and D2 antagonist FCE 23884 on Parkinson's disease.
    Metman LV, Blanchet PJ, de Jong D, Mouradian MM, Chase TN.
    Mov Disord; 1996 May; 11(3):257-60. PubMed ID: 8723141
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. CSF GABA levels in Parkinson's disease.
    de Jong PJ, Lakke JP, Teelken AW.
    Adv Neurol; 1984 May; 40():427-30. PubMed ID: 6695622
    [Abstract] [Full Text] [Related]

  • 11. [Clinical experience in switching patients from standard levodopa to a controlled-release levodopa].
    Leiva Santana C, Galvañ Berenguer B, Gómez García J, Cabello López J.
    Neurologia; 1996 Jan; 11(1):1-9. PubMed ID: 8714169
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Therapeutic results with a new ergoline derivate (8-alpha-amino-ergoline, CU 32-085) in parkinsonian patients.
    Schneider E, Hubener K, Fischer PA.
    Adv Neurol; 1984 Jan; 40():527-9. PubMed ID: 6695631
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Levodopa + carbidopa + entacapone. Entacapone: a second look: new preparations. Parkinson's disease: a modest effect.
    Prescrire Int; 2005 Apr; 14(76):51-4. PubMed ID: 15875340
    [Abstract] [Full Text] [Related]

  • 20. Interaction between bromocriptine and levodopa. Biochemical basis for an improved treatment for parkinsonism.
    Hutt CS, Snider SR, Fahn S.
    Neurology; 1977 Jun; 27(6):503-10. PubMed ID: 577299
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 5.